The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Antitumor and antimetastatic activity of interleukin 12 against murine tumors.
Open accessAbstract
It has recently been demonstrated that in vivo administration of murine interleukin 12 (IL-12) to mice results in augmentation of cytotoxic natural killer (NK)/lymphocyte-activated killer cell activity, enhancement of cytolytic T cell generation, and induction of interferon gamma secretion. In this study, the in vivo activity of murine IL-12 against a number of murine tumors has been evaluated. Experimental pulmonary metastases or subcutaneous growth of the B16F10 melanoma were markedly reduced in mice treated intraperitoneally with IL-12, resulting in an increase in survival time. The therapeutic effectiveness of IL-12 was dose dependent and treatment of subcutaneous tumors could be initiated up to 14 d after injection of tumor cells. Likewise, established experimental hepatic metastases and established subcutaneous M5076 reticulum cell sarcoma and Renca renal cell adenocarcinoma tumors were effectively treated by IL-12 at doses which resulted in no gross toxicity. Local peritumoral injection of IL-12 into established subcutaneous Renca tumors resulted in regression and complete disappearance of these tumors. IL-12 was as effective in NK cell-deficient beige mice or in mice depleted of NK cell activity by treatment with antiasialo GM1, suggesting that NK cells are not the primary cell type mediating the antitumor effects of this cytokine. However, the efficacy of IL-12 was greatly reduced in nude mice suggesting the involvement of T cells. Furthermore, depletion of CD8+ but not CD4+ T cells significantly reduced the efficacy of IL-12. These results demonstrate that IL-12 has potent in vivo antitumor and antimetastatic effects against murine tumors and demonstrate as well the critical role of CD8+ T cells in mediating the antitumor effects against subcutaneous tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced Macrophages
Hsieh, C.-S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., & Murphy, K. M. (1993) · Science · doi:10.1126/science.8097338 · Cited by 3,134
Self-citationRosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704093161501 · Cited by 2,735
Kobayashi, M., Fitz, L., Ryan, M., Hewick, R. M., Clark, S. C., Chan, S., Loudon, R., Sherman, F., Perussia, B., & Trinchieri, G. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.3.827 · Cited by 1,953
Multiple Defects of Immune Cell Function in Mice with Disrupted Interferon-γ Genes
Dalton, D. K., Pitts-Meek, S., Keshav, S., Figari, I. S., Bradley, A., & Stewart, T. A. (1993) · Science · doi:10.1126/science.8456300 · Cited by 1,727
Manetti, R., Parronchi, P., Giudizi, M. G., Piccinni, M. P., Maggi, E., Trinchieri, G., & Romagnani, S. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.4.1199 · Cited by 1,665
Chan, S. H., Perussia, B., Gupta, J. W., Kobayashi, M., Pospísil, M., Young, H. A., Wolf, S. F., Young, D., Clark, S. C., & Trinchieri, G. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.4.869 · Cited by 961
Self-citationWolf, S. F., Temple, P. A., Kobayashi, M., Young, D., Dicig, M., Lowe, L., Dzialo, R., Fitz, L., Ferenz, C., & Hewick, R. M. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.9.3074 · Cited by 845
Self-citationSarmiento, M., Glasebrook, A. L., & Fitch, F. W. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.6.2665 · Cited by 802
Tripp, C. S., Wolf, S. F., & Unanue, E. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3725 · Cited by 776
Self-citationTreatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4
Golumbek, P. T., Lazenby, A. J., Levitsky, H. I., Jaffee, L. M., Karasuyama, H., Baker, M., & Pardoll, D. M. (1991) · Science · doi:10.1126/science.1948050 · Cited by 719
Cited by
Functional diversity of helper T lymphocytes
Abbas, A. K., Murphy, K. M., & Sher, A. (1996) · Nature · doi:10.1038/383787a0 · Cited by 4,450
Interleukin-12 and the regulation of innate resistance and adaptive immunity
Trinchieri, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1001 · Cited by 3,927
Chen, Q., Xu, L., Liang, C., Wang, C., Peng, R., & Liu, Z. (2016) · Nature Communications · doi:10.1038/ncomms13193 · Cited by 1,596
Cytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1252 · Cited by 1,573
Requirement for V α 14 NKT Cells in IL-12-Mediated Rejection of Tumors
Cui, J., Shin, T., Kawano, T., Sato, H., Kondo, E., Toura, I., Kaneko, Y., Koseki, H., Kanno, M., & Taniguchi, M. (1997) · Science · doi:10.1126/science.278.5343.1623 · Cited by 1,237
THE INTERLEUKIN-12/INTERLEUKIN-12-RECEPTOR SYSTEM: Role in Normal and Pathologic Immune Responses
Gately, M. K., Renzetti, L. M., Magram, J., Stern, A. S., Adorini, L., Gubler, U., & Presky, D. H. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.495 · Cited by 1,231
Self-citationCytokines in clinical cancer immunotherapy
Berraondo, P., Sanmamed, M. F., Ochoa, M. C., Etxeberria, I., Aznar, M. A., Pérez-Gracia, J. L., Rodríguez-Ruiz, M. E., Ponz-Sarvise, M., Castañón, E., & Melero, I. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0328-y · Cited by 1,205
Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells
Smyth, M. J., Thia, K. Y. T., Street, S. E. A., Cretney, E., Trapani, J. A., Taniguchi, M., Kawano, T., Pelikan, S. B., Crowe, N. Y., & Godfrey, D. I. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.4.661 · Cited by 829
Interleukin-12: A Cytokine at the Interface of Inflammation and Immunity
Trinchieri, G. (1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60387-9 · Cited by 760
Yang, R., Xu, J., Xu, L., Sun, X., Chen, Q., Zhao, Y., Peng, R., & Liu, Z. (2018) · ACS Nano · doi:10.1021/acsnano.7b09041 · Cited by 698
Interleukin-12 in anti-tumor immunity and immunotherapy
Colombo, M. P., & Trinchieri, G. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00032-6 · Cited by 685
Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases
Lucey, D. R., Clerici, M., & Shearer, G. M. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.4.532 · Cited by 666
Dighe, A. S., Richards, E., Old, L. J., & Schreiber, R. D. (1994) · Immunity · doi:10.1016/1074-7613(94)90087-6 · Cited by 663
Nanoparticle‐Enhanced Radiotherapy to Trigger Robust Cancer Immunotherapy
Chen, Q., Chen, J., Yang, Z., Xu, J., Xu, L., Liang, C., Han, X., & Liu, Z. (2019) · Advanced Materials · doi:10.1002/adma.201802228 · Cited by 661
Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L.-M., Ocampo, C. J., Patterson, R. T., Stirling, D. I., & Kaplan, G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.380 · Cited by 656
Interleukin-12: Biological Properties and Clinical Application
Del Vecchio, M., Bajetta, E., Canova, S., Lotze, M. T., Wesa, A., Parmiani, G., & Anichini, A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0776 · Cited by 601
Chmielewski, M., Kopecky, C., Hombach, A. A., & Abken, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0103 · Cited by 562
New insights into IL-12-mediated tumor suppression
Tugues, S., Burkhard, S. H., Ohs, I., Vrohlings, M., Nussbaum, K., vom Berg, J., Kulig, P., & Becher, B. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.134 · Cited by 558
(1996) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60862-3 · Cited by 510
Interleukin 12: still a promising candidate for tumor immunotherapy?
Lasek, W., Zagożdżon, R., & Jakobisiak, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1523-1 · Cited by 495
Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
Sgadari, C., Angiolillo, A., & Tosato, G. (1996) · Blood · doi:10.1182/blood.v87.9.3877.bloodjournal8793877 · Cited by 469
Stolina, M., Sharma, S., Lin, Y., Dohadwala, M., Gardner, B., Luo, J., Zhu, L., Kronenberg, M., Miller, P. W., Portanova, J., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.1.361 · Cited by 465
Feagan, B. G., Sandborn, W. J., D'Haens, G., Panés, J., Kaser, A., Ferrante, M., Louis, E., Franchimont, D., Dewit, O., Seidler, U., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30570-6 · Cited by 451
Zhang, L., Morgan, R. A., Beane, J. D., Zheng, Z., Dudley, M. E., Kassim, S. H., Nahvi, A. V., Ngo, L. T., Sherry, R. M., Phan, G. Q., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2085 · Cited by 444
Localized Interleukin-12 for Cancer Immunotherapy
Nguyen, K. G., Vrabel, M. R., Mantooth, S. M., Hopkins, J. J., Wagner, E. S., Gabaldon, T. A., & Zaharoff, D. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.575597 · Cited by 431
Tumor-induced immune dysfunction: the macrophage connection
Elgert, K. D., Alleva, D. G., & Mullins, D. W. (1998) · Journal of Leukocyte Biology · doi:10.1002/jlb.64.3.275 · Cited by 426
In vivo natural killer cell activities revealed by natural killer cell-deficient mice
Kim, S., Iizuka, K., Aguila, H. L., Weissman, I. L., & Yokoyama, W. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050588297 · Cited by 424
Trembleau, S., Penna, G., Bosi, E., Mortara, A., Gately, M. K., & Adorini, L. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.2.817 · Cited by 423
Self-citationInhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
Löb, S., Königsrainer, A., Rammensee, H.-G., Opelz, G., & Terness, P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2639 · Cited by 421
Cytokines in cancer immunity and immunotherapy
Smyth, M. J., Cretney, E., Kershaw, M. H., & Hayakawa, Y. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00199.x · Cited by 412
CXC chemokines: the regulatory link between inflammation and angiogenesis
Romagnani, P., Lasagni, L., Annunziato, F., Serio, M., & Romagnani, S. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.02.006 · Cited by 409
Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma
Enk, A. H., Jonuleit, H., Saloga, J., & Knop, J. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971104)73:3<309::aid-ijc1>3.0.co;2-3 · Cited by 386
Interferons and Other Cytokines
Hendrzak, J. A., & Brunda, M. J. (1997) · Cancer Therapeutics · doi:10.1007/978-1-59259-717-8_13 · Cited by 356
Self-citationAntiinflammatory and Immunomodulating Properties of FungalMetabolites
Lull, C., Wichers, H. J., & Savelkoul, H. F. J. (2005) · Mediators of Inflammation · doi:10.1155/mi.2005.63 · Cited by 346
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
Kerkar, S. P., Goldszmid, R. S., Muranski, P., Chinnasamy, D., Yu, Z., Reger, R. N., Leonardi, A. J., Morgan, R. A., Wang, E., Marincola, F. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58814 · Cited by 342
Twelve immunotherapy drugs that could cure cancers
‘Mac’ Cheever, M. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00604.x · Cited by 341
Coughlin, C. M., Salhany, K. E., Gee, M. S., LaTemple, D. C., Kotenko, S., Ma, X., Gri, G., Wysocka, M., Kim, J. E., Liu, L., et al. (1998) · Immunity · doi:10.1016/s1074-7613(00)80585-3 · Cited by 324
Immune Reconstitution and Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation
Guillaume, T., Rubinstein, D. B., & Symann, M. (1998) · Blood · doi:10.1182/blood.v92.5.1471 · Cited by 323
Immune defects observed in patients with primary malignant brain tumors
Dix, A. R., Brooks, W. H., Roszman, T. L., & Morford, L. A. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00203-9 · Cited by 323
Natural killer cells and cancer
Brittenden, J., Heys, S. D., Ross, J., & Eremin, O. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1226::aid-cncr2>3.0.co;2-g · Cited by 319
Schey, S. A., Fields, P., Bartlett, J. B., Clarke, I. A., Ashan, G., Knight, R. D., Streetly, M., & Dalgleish, A. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.052 · Cited by 314
Inflammatory cell infiltration of tumors: Jekyll or Hyde
Talmadge, J. E., Donkor, M., & Scholar, E. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9072-0 · Cited by 313
Kimura, Y., & Okuda, H. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.6.1844 · Cited by 313
Yang, Z.-Z., Grote, D. M., Ziesmer, S. C., Niki, T., Hirashima, M., Novak, A. J., Witzig, T. E., & Ansell, S. M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59806 · Cited by 309
The Anti-Tumor Activity of IL-12: Mechanisms of Innate Immunity That Are Model and Dose Dependent
Smyth, M. J., Taniguchi, M., & Street, S. E. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.5.2665 · Cited by 301
Xie, Y. J., Dougan, M., Jailkhani, N., Ingram, J., Fang, T., Kummer, L., Momin, N., Pishesha, N., Rickelt, S., Hynes, R. O., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817147116 · Cited by 296
NKT cells — conductors of tumor immunity?
Smyth, M. J., Crowe, N. Y., Hayakawa, Y., Takeda, K., Yagita, H., & Godfrey, D. I. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00316-3 · Cited by 294
Tannenbaum, C. S., Tubbs, R., Armstrong, D., Finke, J. H., Bukowski, R. M., & Hamilton, T. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.2.927 · Cited by 294
Zhang, L., Kerkar, S. P., Yu, Z., Zheng, Z., Yang, S., Restifo, N. P., Rosenberg, S. A., & Morgan, R. A. (2011) · Molecular Therapy · doi:10.1038/mt.2010.313 · Cited by 293
Proinflammatory and Immunoregulatory Functions of Interleukin-12
Trinchieri, G. (1998) · International Reviews of Immunology · doi:10.3109/08830189809043002 · Cited by 290
Finkelman, F. D., Madden, K. B., Cheever, A. W., Katona, I. M., Morris, S. C., Gately, M. K., Hubbard, B. R., Gause, W. C., & Urban, J. F. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.5.1563 · Cited by 273
Self-citationWang, Y., Lin, Y.-X., Qiao, S.-L., An, H.-W., Ma, Y., Qiao, Z.-Y., Rajapaksha, R. P. Y. J., & Wang, H. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2016.09.034 · Cited by 266
Cytokines and Immune Response in the Tumor Microenvironment
Mocellin, S., Wang, E., & Marincola, F. M. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200109000-00002 · Cited by 259
Clerici, M., Ferrario, E., Trabattoni, D., Villa, M. L., Clerici, E., Merola, M., Stefanon, B., De Palo, G., Venzon, D. J., & Shearer, G. M. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.3.245 · Cited by 257
Shida, K., Makino, K., Morishita, A., Takamizawa, K., Hachimura, S., Ametani, A., Sato, T., Kumagai, Y., Habu, S., & Kaminogawa, S. (1998) · International Archives of Allergy and Immunology · doi:10.1159/000069458 · Cited by 254
Kerkar, S. P., Muranski, P., Kaiser, A., Boni, A., Sanchez-Perez, L., Yu, Z., Palmer, D. C., Reger, R. N., Borman, Z. A., Zhang, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0735 · Cited by 254
Lucas, M. L., Heller, L., Coppola, D., & Heller, R. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0601 · Cited by 253
Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature
Halin, C., Rondini, S., Nilsson, F., Berndt, A., Kosmehl, H., Zardi, L., & Neri, D. (2002) · Nature Biotechnology · doi:10.1038/nbt0302-264 · Cited by 252
Wang, K. S., Frank, D. A., & Ritz, J. (2000) · Blood · doi:10.1182/blood.v95.10.3183 · Cited by 241
Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages
Stout, R. D., Watkins, S. K., & Suttles, J. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0209073 · Cited by 183
Glassman, C. R., Mathiharan, Y. K., Jude, K. M., Su, L., Panova, O., Lupardus, P. J., Spangler, J. B., Ely, L. K., Thomas, C., Skiniotis, G., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.018 · Cited by 181
Musolino, C., Allegra, A., Innao, V., Allegra, A. G., Pioggia, G., & Gangemi, S. (2017) · Mediators of Inflammation · doi:10.1155/2017/1852517 · Cited by 168
Duan, X., Guan, H., Cao, Y., & Kleinerman, E. S. (2009) · Cancer · doi:10.1002/cncr.24013 · Cited by 79
RETRACTED: IL-12 Deficiency Exacerbates Inflammatory Responses in UV-Irradiated Skin and Skin Tumors
Meeran, S. M., Punathil, T., & Katiyar, S. K. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.140 · Cited by 73
Retracted(2003) · PubMed · Cited by 67
(2001) · PubMed · Cited by 61
IL-12 Regulates an Endothelial Cell-Lymphocyte Network: Effect on Metalloproteinase-9 Production
Mitola, S., Strasly, M., Prato, M., Ghia, P., & Bussolino, F. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.7.3725 · Cited by 58
Gasparri, A. M., Sacchi, A., Basso, V., Cortesi, F., Freschi, M., Rrapaj, E., Bellone, M., Casorati, G., Dellabona, P., Mondino, A., et al. (2019) · Small · doi:10.1002/smll.201903462 · Cited by 37
Zhou, Z., Lafleur, E. A., Koshkina, N. V., Worth, L. L., Lester, M. S., & Kleinerman, E. S. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0092 · Cited by 31
Pizzoferrato, E., Chu, N. R., Hawley, T. S., Lieu, F. H. L., Barber, B. H., Hawley, R. G., Watts, T. H., & Berinstein, N. L. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.18-2217 · Cited by 28
Metadata
- Authors
- Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., & Gately, M. K.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1993-10-01
- Volume
- 178
- Issue
- 4
- Pages
- 1223-1230
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2151707711
- Cited by
- 1,197
- References
- 25
- FWCI
- 16.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.